Last updated: March 1, 2026
What Are Progestin Antagonists?
Progestin antagonists are drugs that inhibit the effects of progesterone by blocking its receptor. They primarily target hormonal pathways involved in contraception, endometrial assessment, and hormone-sensitive cancers. The dominant drug in this class is mifepristone, which also possesses antiglucocorticoid activity.
Market Overview
The global progestin antagonist market has experienced steady growth due to expanding uses in reproductive health, oncology, and endocrine disorders. The market size in 2022 was valued at approximately USD 470 million and is projected to reach USD 900 million by 2027, representing a compound annual growth rate (CAGR) of 13.2%.
Major drivers include increasing demand for non-hormonal contraception, rise in hormone-responsive cancers, and advancements in drug delivery systems.
Key Market Players
| Company |
Key Drugs |
Revenue (2022) |
Market Share (Estimate) |
| Allergan (AbbVie) |
Mifepristone (RU-486) |
USD 120M |
25% |
| Corcept Therapeutics |
Mifepristone (Korlym) |
USD 250M |
53% |
| HRA Pharma |
Mifepristone (Mifegyne) |
USD 40M |
8.5% |
| Other Players |
Various |
USD 60M |
13.5% |
Note: Corcept’s mifepristone is approved for Cushing’s syndrome and psychosis, diversifying from reproductive health.
Patent Landscape
Patent Durations and Expiration
The earliest patents protecting mifepristone in the U.S. filed in 1982, granted in 1984, and expired in 2000. Post-expiration, generic competition increased, lowering prices and expanding access.
Key patent information:
- Initial Composition of Matter Patents: Filed 1982, expired 2000 in the U.S.
- Method of Use Patents: Filed 1990, expired 2010.
- Manufacturing Process Patents: Filed 1983, expired 2003.
Subsequent patents focused on formulations, delivery methods, and new indications. Several of these secondary patents now have expiration dates ranging from 2023 to 2030.
Current Patent Challenges and Opportunities
- Patent cliffs for primary compounds have led to increased generic entry.
- Patent filings for new indications (e.g., breast cancer, uterine fibroids) extend potential exclusivity.
- Patents related to novel delivery systems or combination therapies remain active.
Patent Filings in Global Markets
- European Patent Office (EPO): Patents granted in 1988, expired around 2008.
- Japan Patent Office (JPO): Filings occurred during the late 1980s and early 1990s, with expirations in the late 2000s.
- Developing countries: Patent protection varies; many have expired patents or lack enforcement.
Trends Influencing Patent Strategy
Growing innovation focuses on:
- Selective receptor modulators with improved safety profiles.
- Injectable and implantable formulations for long-acting delivery.
- Combination drugs for enhanced efficacy.
Regulatory and Market Access Factors
- The U.S. FDA approved mifepristone for termination of pregnancy in 2000 under REMS restrictions.
- In Europe, mifepristone is approved for medical abortion, with country-specific regulatory pathways.
- Drug reimbursement policies directly influence market penetration, with high barriers in some regions.
Competitive Developments
- New entrants are developing selective progestin receptor modulators (SPRMs), such as ulipristal acetate, with different mechanisms.
- Patent litigation persists around formulation and use claims, impacting commercialization.
- Companies explore novel indications leveraging existing patent portfolios.
Summary of Key Patent Expirations (Next 5 Years)
| Patent Type |
Expiration Year |
Notes |
| Composition of Matter |
2000 |
Majority expired, generic sales increase |
| Use Patents |
2010 |
Some expire soon, potential for generic entry |
| Formulation Patents |
2023-2030 |
Potential exclusivity for new delivery methods |
Strategic Insights
- Patent expirations for primary active ingredients have increased generic competition.
- Continued innovation in delivery methods and new indications offer patent extension opportunities.
- Competitive advantage may be maintained through robust patent filings with later expiration dates and strategic licensing.
Key Takeaways
- The market for progestin antagonists is growing, driven by demand for contraceptive and oncological applications.
- Mifepristone dominates through established patents and widespread off-label uses.
- Patent expiry has increased generic competition, impacting pricing and market share.
- Innovation focuses on alternative delivery systems and expanding indications.
- Patent strategies remain vital for maintaining exclusivity, especially in emerging markets.
FAQs
-
What are the primary applications of progestin antagonists?
Contraception, medical abortion, and treatment of hormone-responsive cancers.
-
When do existing patents for mifepristone expire?
Composition patents expired in 2000; additional method and formulation patents expire between 2023 and 2030.
-
How does patent expiry affect market competition?
It leads to increased generic entry, lowering prices and expanding access.
-
Are there new drugs competing with mifepristone?
Yes, selective progesterone receptor modulators like ulipristal acetate and emerging compounds in early development stages.
-
What regions offer the highest market potential?
North America, Europe, and select Asian countries with expanding reproductive health markets.
References
[1] International Agency for Research on Cancer (IARC). (2022). Global cancer statistics.
[2] U.S. Food and Drug Administration (FDA). (2022). Mifepristone approval and REMS details.
[3] European Medicines Agency (EMA). (2022). Mifepristone dossier and approval information.
[4] Grand View Research. (2023). Progestin antagonists market size and growth forecast.
[5] PatentScope. (2023). Patent filings related to progestin antagonists.
